COVID-19: DCGI nod to Serum Institute of India for phase 2 and 3 human clinical trials of Oxford vaccine candidate
(WorldNews India)

NEW DELHI: The Drugs Controller General of India (DCGI) has given nod to the Serum Institute of India (SII) for conducting phase 2 and 3 human clinical trials of a -19 vaccine candidate, developed by the University of Oxford, in the country. Government officials told PTI that the approval for conducting phase 2 and 3 clinical trials by the SII was granted by DCGI Dr V G Somani late Sunday night after a thorough evaluation based on the recommendations of the Subject Expert Committee on -19. As a rapid regulatory...